Department of Thoracic Disease, Chiba Cancer Center, 662-2 Nitona-cho, Chuo-ku, Chiba 260-8717, Japan.
Br J Cancer. 2013 Sep 3;109(5):1100-8. doi: 10.1038/bjc.2013.440. Epub 2013 Aug 6.
Chemokines and chemokine receptors not only have significant roles in cancer metastasis and tumorigenesis but also act as antitumour agents. The interaction between the Crk-like adaptor protein (CrkL), which is encoded by the CRKL gene, and non-receptor tyrosine kinase c-ABL is reported to transform many cells into malignant cells. We examined the effects of CC chemokine receptor 7 (CCR7), CCR7 ligands and CrkL and c-ABL in lung adenocarcinoma.
One hundred and twenty patients with lung adenocarcinoma were included in this historical cohort analysis. We examined CCR7 and CCR7 ligands and CrkL and c-ABL mRNA expressions in surgically resected lung adenocarcinoma specimens and evaluated their contribution to prognosis, and the relationship with epidermal growth factor receptor (EGFR) and TP53 mutations.
High CCR7 mRNA expressions indicated better prognoses than those of the groups with low CCR7 mRNA expressions (P=0.007, HR=2.00, 95% CI of ratio: 1.22 -3.31). In lung adenocarcinoma, CrkL and c-ABL mRNAs were related to CCR7 mRNA expression (P<0.0001). CrkL and c-ABL mRNA expressions were influenced by EGFR mutations. A high expression of CCL19 was a good prognostic factor of lung adenocarcinoma.
We propose that CCR7 and CCL19 are clinically good prognostic factors and that CCR7 is strongly related to CrkL and c-ABL kinase mRNA expression in lung adenocarcinoma.
趋化因子和趋化因子受体不仅在癌症转移和肿瘤发生中具有重要作用,而且还可以作为抗肿瘤剂。Crk 样衔接蛋白 (CrkL) 的编码基因 CRKL 与非受体酪氨酸激酶 c-ABL 的相互作用被报道可以将许多细胞转化为恶性细胞。我们研究了 C 型趋化因子受体 7 (CCR7)、CCR7 配体和 CrkL 和 c-ABL 在肺腺癌中的作用。
我们对 120 例肺腺癌患者进行了回顾性队列分析。我们检测了手术切除的肺腺癌标本中 CCR7 和 CCR7 配体以及 CrkL 和 c-ABL 的 mRNA 表达,并评估了它们对预后的影响,以及与表皮生长因子受体 (EGFR) 和 TP53 突变的关系。
高 CCR7 mRNA 表达组的预后优于低 CCR7 mRNA 表达组(P=0.007,HR=2.00,95%CI 比:1.22-3.31)。在肺腺癌中,CrkL 和 c-ABL mRNA 与 CCR7 mRNA 表达相关(P<0.0001)。CrkL 和 c-ABL mRNA 表达受 EGFR 突变的影响。CCL19 的高表达是肺腺癌的良好预后因素。
我们提出 CCR7 和 CCL19 是临床预后良好的因素,并且 CCR7 在肺腺癌中与 CrkL 和 c-ABL 激酶 mRNA 表达密切相关。